A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks
Latest Information Update: 12 Nov 2013
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 22 Jun 2007 New trial record.